



S1: Analytical Test Summary  
 BIO-2008846

$^1\text{H}$ -NMR:




$^1\text{H}$  NMR (500 MHz, METHANOL- $\text{d}_4$ )  $\delta$  8.43 (s, 1H), 8.06 (s, 1H), 7.89-7.96 (m, 2H), 6.66-6.87 (m, 2H), 6.16-6.27 (m, 1H), 5.68-5.80 (m, 1H), 4.44-4.80 (m, 1H), 3.95 (s, 3H), 2.95-3.10 (m, 3H), 2.64-2.92 (m, 4H), 1.86 (s, 3H)


HPLC-purity, acidic conditions:




HPLC-purity, basic conditions:



DSC; melting point:




BIO-2011057




<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ ppm 1.76 (s, 3 H) 2.38 - 2.44 (m, 2 H) 2.86 (ddd, *J*=9.92, 7.17, 3.05 Hz, 2 H) 3.89 (s, 3 H) 4.14 - 4.25 (m, 1 H) 5.54 - 5.62 (m, 1 H) 6.04 - 6.09 (m, 1 H) 6.10 - 6.17 (m, 1 H) 6.81 (d, *J*=2.44 Hz, 1 H) 7.99 (s, 1 H) 8.00 (d, *J*=2.44 Hz, 1 H) 8.16 (s, 1 H) 8.43 (d, *J*=7.94 Hz, 1 H) 8.74 (s, 1 H)


HPLC-purity (base modifier):



HPLC-purity (acid modifier):




Optical purity:






BIO-2012384


$^1\text{H}$ -NMR:




HPLC-purity, acidic conditions:



HPLC–purity, basic conditions:




BIO-2059886




<sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ ppm 1.71 (s, 3 H) 1.76 - 1.85 (m, 1 H) 2.08 - 2.16 (m, 2 H) 2.19 (s, 3 H) 2.71 (ddd, *J*=9.31, 6.56, 3.05 Hz, 2 H) 2.88 - 2.97 (m, 1 H) 3.89 (s, 3 H) 6.76 - 6.80 (m, 1 H) 7.96 - 8.01 (m, 2 H) 8.15 (s, 1 H) 8.71 (d, *J*=1.22 Hz, 1 H)

HPLC-purity (base modifier):



HPLC-purity (acid modifier):



Optical purity:

# AD-H\_MeOH\_DEA\_30


100098\_1248\_02\_mini\_screen\_02 Sm (Mn, 2x3)

2: Diode Array

239

Range: 2.528e-1

Time	Height	Area	Area%
2.1667	250526	38783.64	98.00
2.4317	8937	769.70	2.00




100098\_1248\_02\_mini\_screen\_02

1: Scan ES+

313.17

5.34e6




100098\_1248\_02\_mini\_screen\_02


1: Scan ES+

TIC


1.23e7



S2: TACs for whole brain from all four PET measurements were assessed using kinetic modelling both two-tissue compartment model (2TCM) and graphical analyses using Ichise Multilinear Analysis MA1 (MA1).




The whole brain time-activity curve (TAC) for PET measurements on NHP1 under baseline conditions was analyzed using the two-tissue compartment model (2TCM) for kinetic modeling.




The whole brain time-activity curve (TAC) for PET measurements on NHP1 after pretreatment conditions was analyzed using the two-tissue compartment model (2TCM) for kinetic modeling.







The whole brain time-activity curve (TAC) for PET measurements on NHP1 under baseline conditions was analyzed using the two-tissue compartment model (2TCM) for kinetic modeling.




The whole brain time-activity curve (TAC) for PET measurements on NHP2 after pretreatment conditions was analyzed using the two-tissue compartment model (2TCM) for kinetic modeling.




The whole brain time-activity curve (TAC) for PET measurements on NHP1 under baseline conditions was analyzed using the Multilinear Analysis MA1



The whole brain time-activity curve (TAC) for PET measurements on NHP1 after pretreatment conditions was analyzed using the Multilinear Analysis MA1



The whole brain time-activity curve (TAC) for PET measurements on NHP2 under baseline conditions was analyzed using the Multilinear Analysis MA1



The whole brain time-activity curve (TAC) for PET measurements on NHP2 after pretreatment conditions was analyzed using the Multilinear Analysis MA1